Abstract
BackgroundABL503 (also known as TJ-L14B) is a bispecific antibody designed to simultaneously target PD-L1 and 4–1BB, and functions as both ‘PD-(L)1 inhibitor’ and ‘PD-L1-dependent 4–1BB agonist’, overcoming the known 4–1BB...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
